Biography for Alison Bryant
Alison Bryant began at FierceVaccines in 2012. She has covered local politics, growth and development and breaking news in Maryland and Vermont. Her work has been published in The Washington Post, The Burlington Free Press and The Gazette. In her free time, Bryant enjoys reading, creative writing and yoga. She's based in Washington, D.C. and can be reached at email@example.com. Follow @AlisonBFierce on Twitter.
Articles by Alison Bryant
Low efficacy of this season's flu vaccine highlights the need for vaccinemakers to develop a better, longer-lasting shot. Only 56% of people who received the jab were protected from influenza, the U.S. Centers for Disease Control and Prevention reports, and the elderly were among the least shielded.
After rejecting Dynavax's ($DVAX) hepatitis B vaccine Heplisav for safety issues, the FDA said it will meet with the company in 6 weeks' time to discuss a more restricted use of the vaccine.
Adding more children's vaccines to the recommended package should--in theory--save more lives. But rising prices may actually mean fewer children are vaccinated.
National Institutes of Health-funded researchers aim to put a stop to Shigella, an illness found most commonly in children, with two related vaccine candidates.
An Indian high court on Friday quashed India's income tax department's claim that Sanofi owed more than $185 million in capital gains tax in relation to its 2009 buyout of Shantha Biotechnics.
Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
Computer technology is being used more widely in upping vaccination rates worldwide. A team of researchers, epidemiologists and software developers at Boston Children's Hospital rolled out a free online service that helps people locate nearby vaccine providers in an effort to boost immunization numbers.
On Feb. 15, Australian boys began receiving Gardasil as part of a $21 million program geared toward vaccinating 12- and 13-year-olds.
Jennerex's genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival by more than a year, a study shows.
Researchers have discovered cases of whooping cough caused by a germ that may stand up to the vaccine.